{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:25:36Z","timestamp":1778167536204,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10096-025-05065-0","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:54:30Z","timestamp":1740401670000},"page":"1139-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety of high-dose daptomycin in obese patients: a multicentric retrospective study"],"prefix":"10.1007","volume":"44","author":[{"given":"Vasco","family":"Dias Meireles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mentine","family":"Airaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elouan","family":"Demay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Cazanave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Xuereb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Lazaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Bacle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin","family":"Lahouati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"5065_CR1","unstructured":"Ob\u00e9sit\u00e9 et surpoids [Internet]. [cited 2024 Jul 25]. Available from: https:\/\/www.who.int\/fr\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"issue":"8","key":"5065_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1592\/phco.27.8.1081","volume":"27","author":"MP Pai","year":"2007","unstructured":"Pai MP, Bearden DT (2007) Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27(8):1081\u20131091","journal-title":"Pharmacotherapy"},{"issue":"7","key":"5065_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1473-3099(06)70523-0","volume":"6","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Kompoti M (2006) Obesity and infection. Lancet Infect Dis 6(7):438\u2013446","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"5065_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40005-013-0073-4","volume":"43","author":"SJ Cho","year":"2013","unstructured":"Cho SJ, Yoon IS, Kim DD (2013) Obesity-related physiological changes and their pharmacokinetic consequences. J Pharm Invest 43(3):161\u2013169","journal-title":"J Pharm Invest"},{"issue":"4","key":"5065_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","volume":"47","author":"AS Alobaid","year":"2016","unstructured":"Alobaid AS, Hites M, Lipman J, Taccone FS, Roberts JA (2016) Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review. Int J Antimicrob Agents 47(4):259\u2013268","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"5065_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2165\/00003088-199019030-00005","volume":"19","author":"R Zini","year":"1990","unstructured":"Zini R, Riant P, Barr\u00e9 J, Tillement JP (1990) Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (part II). Clin Pharmacokinet 19(3):218\u2013229","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"5065_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/infdis\/138.4.499","volume":"138","author":"SN Schwartz","year":"1978","unstructured":"Schwartz SN, Pazin GJ, Lyon JA, Ho M, Pasculle AW (1978) A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis 138(4):499\u2013505","journal-title":"J Infect Dis"},{"issue":"1","key":"5065_CR8","first-page":"8","volume":"37","author":"M Kotlyar","year":"1999","unstructured":"Kotlyar M, Carson SW (1999) Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 37(1):8\u201319","journal-title":"Int J Clin Pharmacol Ther"},{"key":"5065_CR9","unstructured":"cubicin-epar-product -information_en.pdf [Internet]. [cited 2024 Aug 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cubicin-epar-product-information_en.pdf"},{"key":"5065_CR10","unstructured":"Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations - PMC [Internet]. [cited 2024 Aug 11]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4776011\/"},{"issue":"1","key":"5065_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/0091270004269562","volume":"45","author":"BH Dvorchik","year":"2005","unstructured":"Dvorchik BH, Damphousse D (2005) The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 45(1):48\u201356","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"5065_CR12","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/phar.1298","volume":"33","author":"PB Bookstaver","year":"2013","unstructured":"Bookstaver PB, Bland CM, Qureshi ZP, Faulkner-Fennell CM, Sheldon MA, Caulder CR et al (2013) Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Pharmacotherapy 33(12):1322\u20131330","journal-title":"Pharmacotherapy"},{"issue":"8","key":"5065_CR13","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/jac\/dkac164","volume":"77","author":"YC Chuang","year":"2022","unstructured":"Chuang YC, Lin HY, Yang JL, Lin CY, Huang SH, Wang JT et al (2022) Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin. J Antimicrob Chemother 77(8):2278\u20132287","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"5065_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","volume":"48","author":"N Safdar","year":"2004","unstructured":"Safdar N, Andes D, Craig WA (2004) Vivo pharmacodynamic activity of Daptomycin. Antimicrob Agents Chemother 48(1):63\u201368","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5065_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000077278","volume":"50","author":"PK Dandekar","year":"2004","unstructured":"Dandekar PK, Tessier PR, Williams P, Zhang C, Nightingale CH, Nicolau DP (2004) Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model. Chemotherapy 50(1):11\u201316","journal-title":"Chemotherapy"},{"issue":"3","key":"5065_CR16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","volume":"45","author":"A Louie","year":"2001","unstructured":"Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL (2001) Pharmacodynamics of Daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 45(3):845\u2013851","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"5065_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.hrtlng.2005.09.010","volume":"35","author":"BA Cunha","year":"2006","unstructured":"Cunha BA, Eisenstein LE, Hamid NS (2006) Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged\/high-dose daptomycin without toxicity. Heart Lung 35(3):207\u2013211","journal-title":"Heart Lung"},{"key":"5065_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13756-016-0158-8","volume":"5","author":"P Uppal","year":"2016","unstructured":"Uppal P, LaPlante KL, Gaitanis MM, Jankowich MD, Ward KE (2016) Daptomycin-induced eosinophilic pneumonia - a systematic review. Antimicrob Resist Infect Control 5:55","journal-title":"Antimicrob Resist Infect Control"},{"key":"5065_CR19","doi-asserted-by":"crossref","unstructured":"Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC (2009 Jul) Safety and clinical outcomes when utilizing high-dose (> or = 8\u00a0mg\/kg) daptomycin therapy. Ann Pharmacother 43(7):1211\u20131219","DOI":"10.1345\/aph.1M085"},{"key":"5065_CR20","first-page":"204993611882023","volume":"6","author":"AN Fox","year":"2019","unstructured":"Fox AN, Smith WJ, Kupiec KE, Harding SJ, Resman-Targoff BH, Neely SB et al (2019) Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight. Ther Adv Infect Dis 6:2049936118820230","journal-title":"Ther Adv Infect Dis"},{"issue":"8","key":"5065_CR21","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/cid\/ciac128","volume":"75","author":"M Chuma","year":"2022","unstructured":"Chuma M, Nakamoto A, Bando T, Niimura T, Kondo Y, Hamano H et al (2022) Association between Statin Use and Daptomycin-related Musculoskeletal adverse events: a mixed Approach combining a Meta-analysis and a disproportionality analysis. Clin Infect Dis 75(8):1416\u20131422","journal-title":"Clin Infect Dis"},{"issue":"5","key":"5065_CR22","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1111\/bcp.15172","volume":"88","author":"M Samura","year":"2022","unstructured":"Samura M, Takada K, Hirose N, Kurata T, Nagumo F, Koshioka S et al (2022) Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: a systematic review and meta-analysis. Br J Clin Pharmacol 88(5):1985\u20131998","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"5065_CR23","first-page":"117","volume":"74","author":"N Gr\u00e9goire","year":"2019","unstructured":"Gr\u00e9goire N, Marchand S, Ferrandi\u00e8re M, Lasocki S, Seguin P, Vourc\u2019h M et al (2019) Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. J Antimicrob Chemother 74(1):117\u2013125","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05065-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T12:54:36Z","timestamp":1746708876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05065-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["5065"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05065-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was conducted following MR-004 reference methodology, relating to the processing of retrospective and prospective personal data implemented in the framework of studies and evaluations in the field of health in France. This study was approved by Data Protection Officer. Patients were informed when collecting personal data in order to comply with EU General Data Protection Regulation. According to MR-004 and French legislation, no longer needs written consent from patient prior to the use of their data. Patients did not object to analysis of their data for research issue.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}